GlassScriptPhysician profile
Daniel Youngjun Choi
NPI 1801164827
$8,785.99
in general payments reported to CMS, 2019-2025
26 companies · $5,422 in 2025
The $5,422 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $266 · 2021: $228 · 2022: $258 · 2023: $1,311 · 2024: $712 · 2025: $5,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,400 · Food and Beverage: $2,032 · Education: $12.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,399.75 |
| Food and Beverage | $2,031.52 |
| Education | $12.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $4,964.52 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
| Glaukos Corporation | $825.00 | 2023 | Kxl System (Not Refurbished) |
| Alcon Vision LLC | $584.49 | 2019-2025 | Rocklatan, Unity, Clareon |
| Allergan, INC. | $463.76 | 2019-2021 | |
| Abbvie INC. | $456.95 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Aerie Pharmaceuticals, INC. | $297.12 | 2019-2021 | |
| Depuy Synthes Sales INC. | $206.71 | 2024-2025 | Trialtis, Na, Skyline |
| Johnson & Johnson Surgical Vision, INC. | $130.00 | 2023 | Catalys System |
| Dompe US, INC. | $100.00 | 2025 | Oxervate |
| Nova Eye, INC. | $93.75 | 2024 | |
| Novo Nordisk INC | $88.05 | 2019 | |
| Sight Sciences, INC. | $88.05 | 2022-2023 | Omni Surgical System |
| Thea Pharma INC. | $87.34 | 2023-2024 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $69.46 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $50.70 | 2023-2024 | Vyzulta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $45.50 | 2024 | Rayone Emv, Omidria, Rayone Aspheric |
| Optos, INC. | $40.54 | 2022 | |
| Biotissue Holdings INC. | $40.13 | 2024 | |
| Ocular Therapeutix, INC. | $38.87 | 2021-2022 | |
| Oyster Point Pharma, INC. | $25.62 | 2024 | Tyrvaya |
| Horizon Therapeutics Plc | $24.26 | 2022 | |
| Sun Pharmaceutical Industries INC. | $19.22 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.94 | 2021 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| New World Medical,INC. | $9.77 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.